PDS Biotechnology Corporation received a new patent from the Japan Patent Office on December 9 2025, granting Patent No. 7783866 for its investigational immunotherapy Versamune HPV (PDS0101). The patent covers broad composition‑of‑matter claims and methods of use that protect the product’s unique antigen‑targeting platform and its combination with checkpoint inhibitors.
The new Japanese patent complements PDS Biotechnology’s existing portfolio, which includes U.S., China, Australia and Hong Kong patents that together secure a multi‑decade exclusivity window. With the Japanese grant, the company’s protection now extends into the 2040s, aligning with anticipated U.S. biologics exclusivity and providing a robust defense against generic competition in a rapidly expanding market.
Versamune HPV targets HPV‑16‑related head‑and‑neck cancers, a disease area projected to grow as HPV vaccination rates rise and screening improves. The global HPV‑associated disorders market was valued at $18.5 billion in 2024 and is expected to reach $28.5 billion by 2033, while Japan’s cancer‑vaccine market alone is projected to hit $4.6 billion by 2034. The patent therefore positions PDS Biotechnology to capture a larger share of this lucrative opportunity.
Frank Bedu‑Addo, President and CEO, said the new patent “further strengthens our global IP portfolio and reinforces the robust intellectual property position supporting our growth.” Investors responded positively to the announcement, reflecting confidence in the company’s long‑term commercial prospects.
The patent grant is a key milestone in PDS Biotechnology’s strategy to secure a durable competitive advantage for Versamune HPV, reinforcing its ability to monetize the product once regulatory approvals are achieved and to defend against potential generic entrants in Japan and beyond.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.